ELAN — Elanco Animal Health Incorporated stock price, charts and financials

QT62Elanco Animal Health Incorporated

Elanco Animal Health Incorporated (NYSE: ELAN) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
22.27
+0.15+0.70%
ELANQT62Elanco Animal Health Incorporated·NYSE
22.27+0.70%
News
Up 0.7% — Elanco Animal Health Q2 Earnings Call Highlights (marketbeat.com).
Medium confidence
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index-P/E-EPS (ttm)-0.49Insider Own1.13%Shs Outstand499.45MPerf Week-16.12%
Market Cap11.05BForward P/E17.92EPS next Y1.23Insider Trans0.17%Shs Float494.82MPerf Month-10.15%
Enterprise Value14.44BPEG0.34EPS next Q-Inst Own-Short Float7.24%Perf Quarter-7.87%
Income-198.86MP/S2.20EPS this Y324.48%Inst Trans-Short Ratio6.23Perf Half Y-9.01%
Sales5.02BP/B1.68EPS next Y12.23%ROA-1.47%Short Interest35.82MPerf YTD-2.25%
Book/sh-P/C17.54EPS next 5Y8.69%ROE-3.02%52W High28.17 -20.94%Perf Year58.11%
Cash/sh-P/FCF32.40EPS past 3/5Y-ROIC3.92%52W Low15.61 42.71%Perf 3Y88.58%
Dividend Est.-EV/EBITDA18.65Sales past 3/5Y2.25% 7.57%Gross Margin52.59%Volatility6.89% 4.13%Perf 5Y-39.35%
Dividend TTM-EV/Sales2.88EPS Y/Y TTM-172.06%Oper. Margin9.20%ATR (14)1.22Perf 10Y-
Dividend Ex-Date-Quick Ratio1.09Sales Y/Y TTM10.23%Profit Margin-3.96%RSI (14)31.64Recom2.38
Dividend Gr. 3/5Y-Current Ratio2.05EPS Q/Q8.11%SMA20-12.86%Beta1.64Target Price28.67
Payout0.00%Debt/Eq0.59Sales Q/Q14.92%SMA50-10.33%Rel Volume3.50Prev Close22.12
Employees9,900LT Debt/Eq0.60EarningsNov 04SMA200-6.08%Avg Volume6.32MPrice22.27
IPO DateSep 20, 2018Option/ShortYes / YesEPS/Sales Surpr.15.75% 7.35%Net Debt/EBITDA4.38Volume22,073,546Change0.70%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-06-26ReiteratedKeyBancOverweight$29$30
Jul-22-26ReiteratedMorgan StanleyEqual Weight$23$26
May-15-26ReiteratedMorgan StanleyEqual Weight$24$23
Feb-25-26ReiteratedKeybancOverweight$27$29
Feb-24-26ReiteratedLeerink PartnersOutperform$18$30
Jan-29-26ReiteratedUBSBuy$27$30
Jan-22-26UpgradePiper SandlerNeutralOverweight$12$30
Dec-18-25ReiteratedMorgan StanleyEqual Weight$37$22
Dec-08-25InitiatedBarclaysOverweight$22$30
Nov-20-25InitiatedKeyBancOverweight$27
Latest News
Aug-08-26
Aug-07-26
Aug-06-26
Aug-05-26
Jul-31-26
Jul-29-26
Company

Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue5,0204,7154,439
Cost of Goods Sold Incl. D&A2,3802,6652,530
Gross Profit2,6402,0501,909
Selling, General and Administrative Excl. Other1,5191,4301,314
Research and Development371368344
Other Operating Expense
28800
Operating Income462252251
Interest Expense259220339
Unusual Expense
Non-Operating Income (Expense)-369-256576
Net Income Before Taxes-166-224488
Income Taxes338150
Consolidated Net Income-199-232338
Net Income From Continuing Operations-199-232338
Net Income-199-232338
EPS (Recurring)-0.41-0.470.68
EPS (Basic, Before Extraordinaries)-0.41-0.470.68
EPS (Diluted)-0.40-0.470.68
EBITDA7746761,489
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio17.81
Price To Sales Ratio2.222.381.35
Gross Margin52.5943.4843.01
Operating Margin9.205.345.65
Net Margin-3.96-4.927.61
Shares Outstanding500496494
Market Capitalization11,13811,2245,982
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$28.87$24.48$20.09$15.69$11.30 Close Price0.00K234.48K468.95K703.43K937.91KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Modi Rajeev A.SEE REMARKSMay 15 '26Buy20.354,91199,939160,812May 19
Simmons Jeffrey NPRESIDENT, CEO AND DIRECTORMay 15 '26Buy20.094,97199,843171,971May 19
Kurzius Lawrence ErikDirectorDec 12 '25Buy21.3010,000213,000131,773Dec 16
Modi Rajeev A.SEE REMARKSDec 11 '25Buy21.334,50095,985123,082Dec 15
VanHimbergen Robert MEVP and CFODec 11 '25Buy21.646,950150,426124,233Dec 15
Simmons Jeffrey NPRESIDENT, CEO AND DIRECTORDec 11 '25Buy21.7522,000478,496167,000Dec 15
Kurzius Lawrence ErikDirectorMar 11 '25Buy10.2010,000102,000111,459Mar 11
Kurzius Lawrence ErikDirectorMar 07 '25Buy10.9010,000109,000101,459Mar 11
HOOVER R DAVIDDirectorMar 05 '25Buy10.9025,000272,558210,000Mar 07
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.